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Changes to the SC List of Reportable Conditions for 2010 
Chasisity Brown Springs, MSPH, Influenza Epidemiologist 
Division of Acute Disease Epidemiology 
As authorized by South Carolina Statute #44-20-10 and 
Regulation #61-20, the S.C. Department of Health and 
Environmental Control (DHEC) updates the list of 
Reportable Conditions in January of each year.  Revisions 
to the list of reportable conditions are based on many 
factors, including: (1) the need for DHEC to conduct 
surveillance on new conditions or to increase surveillance 
on certain existing conditions in order to protect the 
health of the public and (2) changes in reporting 
requirements from the U.S. Centers for Disease Control 
and Prevention (CDC). 
The following revisions have been made to the 2009 List 
of Reportable Conditions: 
New for 2010 
♦ Influenza hospitalizations (aggregate report of totals) 
♦ Influenza laboratory confirmed cases by RT-PCR, 
DFA, and IFA 
♦ Names of organisms have been added for some 
conditions 
♦ Rabies post-exposure prophylaxis, when 
recommended, has been added. 
Revisions to the List of Reportable Conditions 
♦ Rabies (human) has been moved to immediately 
reportable by phone. 
♦ Influenza, positive virus culture isolates has been 
reworded to “Influenza, lab-confirmed cases (culture, 
RT-PCR, DFA, IFA)”.  
♦ Influenza A, avian or other novel has been updated to 
read “Influenza A, avian or other novel (not H1, H3, 
or 2009 H1N1)”. 
♦ The footnote, "report weekly only total number of 
positive results; individual case reporting is not 
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Are you using 2009 H1N1 Live Attenuated 
Influenza Vaccine (LAIV) in your Practice?  
Riyadh D. Muhammad, MD, MPH, Medical Epidemiologist 
Division of Acute Disease Epidemiology 
Influenza A (H1N1) 2009 vaccines first became available in South 
Carolina in October 2009.  Then and now, much of the H1N1 
vaccine supply has been the intranasal formulation, LAIV 
(MedImmune).  Since H1N1 vaccine supplies have been increasing 
slowly, it is important for medical providers to administer LAIV to as 
many appropriate population groups as possible (Box 1).  Using 
LAIV in your practice would allow more of your patients to 
be protected from influenza.  Each year, influenza causes 
approximately 36,000 deaths in the United States1.  This year, the 
H1N1 pandemic has led to higher than normal flu activity, with 
younger age groups more severely affected than is seen in typical 
flu seasons2.  
(Continued on page 11) 
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necessary" has been removed.  A note has been 
added next to influenza hospitalizations and positive 
rapid flu tests that reads “aggregate report of totals.” 
♦ Footnote (7) has been clarified.  It now indicates 
that, for designated conditions, labs are requested to 
submit isolates, broths, and serum to the DHEC 
Bureau of Laboratories for confirmatory testing or 
genotyping. 
♦ A new footnote has been added: (11) to indicate that, 
for influenza deaths and hospitalizations, only lab-
confirmed should be reported; the footnote also 
clarifies for which tests results are reportable.  The 
form” SC Laboratory Confirmed Influenza 
Hospitalizations and Death Summary Report (for 
Hospital Use)” should be used to submit this 
information to regional public health offices.  See 
influenza reporting article, page 3 of this edition of 
the Epi Notes, for further details. 
♦ A new footnote has been added: (12) to indicate that 
rabies post-exposure prophylaxis should be reported 
when recommended by a physician. 
♦ Under "how to report", 4. HIV and AIDS, STD/HIV 
Surveillance Division has been changed to Division of 
Surveillance and Technical Support. 
Revisions to the 2010 Laboratory Reporting List 
♦ Rabies virus (human) has been moved to immediately 
reportable by phone 
♦ Influenza, positive virus culture isolates has been 
changed (reworded) to lab-confirmed cases (culture, 
RT-PCR, DFA, IFA).  
♦ Influenza A, avian or other novel has been updated to 
read “influenza A, avian or other novel (not H1, H3, 
or 2009 H1N1)”. 
♦ The footnote, "report weekly only total number of 
positive results; individual case reporting is not 
necessary" has been removed. A note has been 
added next to influenza hospitalizations and positive 
rapid flu tests that says (aggregate report of totals). 
♦ A new footnote has been added: (10) to indicate that, 
for influenza hospitalizations and deaths, only lab-
confirmed cases should be reported; it clarifies for 
which tests results are reportable. 
♦ Under "how to report", 4. HIV and AIDS, STD/HIV 
Surveillance Division has been changed to Division of 
Surveillance and Technical Support. 
Revisions to the Disease Reporting Card 
♦ Section has been added to include the species and 
date if rabies post exposure prophylaxis (PEP) is 
recommended 
Accessing the New Forms and Posters 
The above changes may be found: 
♦ On the DHEC Web site, linked from the Bureau of 
Disease Control page: http://www.scdhec.gov/health/
disease/index.htm,  
♦ On the 2010 DHEC Disease Reporting Card (color is 
yellow for 2010), and 
♦ On the 2010 List of Reportable Conditions poster or 
the 2010 Laboratory List of Reportable Conditions. 
Both the Disease Reporting Cards and the posters (sizes 8 
by 11 inches and 12 by 24 inches) are available from the 
DHEC regional public health departments or from the 
DHEC Division of Acute Disease Epidemiology in 
Columbia.  
(Continued from page 1) 
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The SC 2010 List of Reportable Conditions has been updated to make influenza hospitalizations reportable, to clarify 
which results are valid for reporting deaths and hospitalizations, and to include laboratory confirmation by RT-PCR, DFA, 
and IFA.  On August 28, 2009, a Health Advisory was sent out informing recipients that aggregate totals of influenza 
hospitalizations were to be reported to DHEC (review the Health Advisory here: http://www.scdhec.gov/health/disease/
han/docs/10181-DAD-08-28-09-H1N1.pdf).  
Beginning in 2010, influenza hospitalizations (aggregate report of totals) have been added to the List of Reportable 
Conditions.  Total numbers of influenza hospitalizations by age group should be reported weekly on Monday by hospitals 
to the regional health department using the SC laboratory confirmed influenza hospitalization and mortality summary 
report worksheet (this page or see http://www.scdhec.gov/health/disease/han/docs/10181-DAD-08-28-09-H1N1.pdf).  
Hospitals should also use this worksheet to report total numbers of influenza deaths by age group at the same time that 
they report hospitalizations.  However, this worksheet does not take the place of name-based reporting of influenza 
deaths.  
On the 2010 list of reportable conditions, both influenza deaths and hospitalizations are accompanied by a footnote (11) 
which states, “Report lab-confirmed only.  Laboratory confirmation includes culture, RT-PCR, DFA, IFA, or rapid test.  For 
deaths, confirmation also includes autopsy results 
consistent with influenza.”  
For the 2010 list, the verbiage “influenza, positive virus 
culture isolates” has been updated to include additional 
laboratory tests.  The condition is now listed as “lab-
confirmed cases (culture, RT-PCR, DFA, IFA)”. 
The footnote (#) for rapid tests has been removed.  
There is a note next to positive rapid flu tests within 
the text of the list that says, “aggregate report of 
totals”.  
Influenza conditions now appear on the list as follows: 
♦Deaths (all ages) (11 = lab confirmed only) 
♦Hospitalizations (aggregate report of totals) (11 = 
lab confirmed only) 
♦Lab-confirmed cases (culture, RT-PCR, DFA, IFA) 
♦Positive rapid flu tests (aggregate report of totals) 
Changes in the 2010 List of Reportable Conditions: Influenza  
Chasisity Brown Springs, MSPH, Influenza Epidemiologist 
Division of Acute Disease Epidemiology 
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Changes to the SC DHEC Disease Reporting Card for 2010 
New Reportable Condition: Rabies post-
exposure prophylaxis (PEP) recommended (12). 
Footnote 12 reads:  Rabies post exposure 
prophylaxis should be reported when a 
physician recommends it. 
Rabies PEP – If rabies post-exposure prophylaxis 
(PEP) was recommended following a bite, enter 
the species of animal and the date that PEP 
was recommended. 
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Question:  What is known about effectiveness of 
vaccines against the current pandemic H1N1 influenza 
strain, and more generally, what is the effectiveness of 
influenza vaccines and what kind of protection can society 
really expect from them? 
Answer:  Issues relating to vaccine effectiveness are 
more commonly discussed in specialized epidemiology 
journals and the like.  Nonetheless, because of the 
attention focused on pandemic H1N1 influenza since it 
emerged last April, there has been unusual, though quite 
natural, interest this year relating to the “effectiveness” of 
influenza vaccines.  In reply to your question, we 
therefore present here:  
i) a short introduction to vaccine effectiveness 
calculations;  
ii) examples of factors that can affect influenza 
vaccine effectiveness; and  
iii) brief perspectives regarding the benefits of 
influenza vaccination for individual vaccinees as 
well as for society. 
1.  Calculating Vaccine Effectiveness.  Both the 
scientific literature and the lay press speak about vaccine 
effectiveness (VE) by means of numbers, usually 
expressed as a percent.  Thus, a basic question about 
effectiveness might ask: “What does it actually mean 
when we say a vaccine is 75% (or 85% or even 
95%) effective?”  Someone considering the question 
for the first time might propose as a first reply something 
like, “That means the vaccine works 75% of the time.”  A 
somewhat more sophisticated answer might be 
something along these lines:  “The vaccine can reduce 
the risk of getting influenza by 75%,” and this wording 
could certainly serve as a useful explanation for patients.  
Both of these intuitive answers are on the right track in 
an informal way, but we will present here the more 
formal way in which VE is typically quantified in 
epidemiological studies. 
Many standard references1,2 express VE through the 
following formula: 
 
Actually (see the worked example below) this calculation 
of VE will yield a decimal fraction such as. “0.85” which 
would be fine, except that since VE is more commonly 
expressed as a percent  it is customary to indicate that 
the result shown above is to be multiplied by 100 so that 
VE will be expressed as a percent – in this case 85% --  
rather than as a decimal.  Thus, to convert the decimal to 
a percent, we add to the formula shown above a final 
multiplication by 100 so that we have: 
Either way, this formula is helpful conceptually because it 
shows that a formal calculation of VE requires information 
about the occurrence of disease not only among 
vaccinated persons, but also among the unvaccinated!  
The way the formula works in practice can best be 
explained by working through an illustrative example, 
which summarizes influenza season events for a 
hypothetical cohort of 2000 persons, where: 
For example, starting with: 
This shows that 50 of the 1000 vaccinated persons in the 
cohort developed influenza during the flu season.  The 
“attack rate” among these vaccinated (ARV) individuals is 
calculated as follows:  
We then consider what happened to the other 1000 
persons in the cohort who did not receive influenza 
vaccine.   
 
This shows that 200 of the 1000 unvaccinated persons in 
the cohort developed influenza during the flu season.  
The “attack rate” among the unvaccinated (ARV) can 
then also be calculated:  
(Continued on page 8) 
V- 200 1000
Ask Epi: Perspectives on Effectiveness of Influenza Vaccines  
Eric R. Brenner, MD, Medical Epidemiologist 
Division of Acute Disease Epidemiology 
ARU
ARVVE −= 1 Where:     ARU = attack rate in the unvaccinated 




V+ indicates vaccinated 
persons 
D+ indicates disease 
(influenza) occurred 
V- indicates unvaccinated 
persons 
D- indicates disease (influenza) 
did not occur 
D+ D-
V+ 50 1000
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Then, for conceptual clarity, and to use the typical layout 
commonly used in many epidemiologic studies, we can 
summarize the experience of both the vaccinated and the 
unvaccinated in a 2x2 table: 
Then, applying the VE formula: 
Note: In this example, the calculation did not require use 
of the numbers in two cells of the right hand column of 
the 2x2 table.  These numbers would easily have been 
available by subtraction (e.g., 1000-50 = 950), but are 
not shown here because they are not used in the VE 
calculation. 
This result can be interpreted several ways.  First, we can 
see that the vaccinated, though they were not totally 
protected from influenza during the flu season, did have a 
much lower risk of developing influenza than the 
unvaccinated.  In prose, the numerical line of reasoning 
might run as follows: “If the group of 1000 vaccinees had 
NOT received vaccine, their attack rate would also have 
been 0.20 (since their risk would then have been identical 
to that of the unvaccinated), and, accordingly the group 
would thus have had 200 cases.  But, through the 
benefits of vaccine, the group only experienced 50 cases; 
and this reduction, from 200 to 50 cases, indeed 
corresponds to a reduction of 75%. 
Alternatively, this same reduction in cases due to 
vaccination could be displayed graphically (see figure 
opposite). 
The numerical reasoning and the graphical display are of 
course equivalent, and just offer complementary 
explanations of the concept of vaccine effectiveness.  
Either way, the main point is that vaccine effectiveness is 
studied and calculated not based solely on what happens 
to vaccinated persons, but also based on what happens 
to unvaccinated persons in the same population.  In 
effect then, the concept of VE provides a way to compare 
the difference between what happens to the two groups.  
Though VE studies actually come in several flavors, even 
the more “sophisticated” vaccine effectiveness study 
designs can be understood as variants of the basic 
approach outlined above. 
Note: In observational studies, vaccine effectiveness is 
typically assessed through either prospective or 
retrospective cohort studies using very much the type of 
reasoning and calculation shown above, or through case-
control studies3, though other variant study designs such 
as the “screening method” 4,5 or “case-cohort” methods6 
are also used.  In experimental settings, VE (in that 
context referred to as “vaccine effectiveness”) is assessed 
through randomized-control trials (RCTs) 7, 8, 9. 
2.  Effectiveness of Influenza Vaccines.  
The current USPHS Advisory Committee on 
Immunization Practice (ACIP) statement on 
seasonal influenza vaccines10 contains four 
pages of summary information about influenza VE trials 
conducted in recent decades in which VE has been found 
to range from 20% to 91% (mean of values listed: 60%).  
At first glance, such a broad range of VE estimates is 
disconcerting.  However, on closer reading, it turns out 
that much of this variability (see Table 1) depends on a 
series of factors which, when considered individually or in 
combination, can quite understandably affect VE.  
Thus VE would naturally be expected to be high when 
vaccinees were healthy young adults, when the year’s 
vaccine virus strains closely matched circulating virus, and 
where the outcome measured was laboratory confirmed 
influenza.  On the other hand, we would reasonably 
expect VE to be lower when given to a group of elderly 
(Continued from page 7) 
(Continued on page 9) 
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persons with underlying chronic and or immunologic 
conditions, in a year when there was a poor fit between 
vaccine virus and circulating strains, and where the 
outcome measured was occurrence of influenza-like 
illness (ILI) which of course may be due to viruses other 
than influenza.   
Nonetheless, overall vaccine effectiveness in a given year 
will be some type of mix or average of higher and lower 
VEs, and it is easy to see that overall vaccine 
effectiveness in a population might be of the order of 
70% rather than 90%+ as may be expected with certain 
other vaccines (e.g., measles vaccine.) 
3.  Potential impact of influenza vaccines.  Influenza 
can affect a large proportion of the population in any 
given year, up to 10-20% or more.  Therefore, even an 
influenza vaccine of somewhat modest VE, when applied 
to such a large number of potential cases, may prevent 
many more US deaths each year than could a vaccine 
against another disease such as measles, even though 
measles VE is in fact higher than influenza VE.  Table 2 
(page 10) illustrates this line of reasoning with some 
sample numbers and calculations and comparing the 
impacts of influenza and measles vaccination on 
mortality.  
4.  Summary.  While it is true that the effectiveness of 
influenza vaccine for certain individuals (e.g., the very 
elderly and/or persons with certain underlying 
conditions / see  Table 1) should not be overestimated, 
conversely, the potential beneficial impact of influenza 
vaccines for society as a whole should not be 
underestimated.  Further, when considering these issues, 
the “indirect benefits” of influenza vaccine should also be 
considered.  That is, vaccinated persons not only benefit 
from a reduction of their own risk of developing influenza, 
but as a group they will also be less likely to infect their 
close contacts in various settings such as work, school, 
and home.  Reducing transmission in these settings offers 
beneficial impact respectively:  (i) for continuity of 
business operations; (ii) for prevention of large-scale 
school absenteeism and consequent risk of school 
closures; and (iii) for protection of vulnerable infants.   
Epidemiologic studies to evaluate formally the 
effectiveness of this year’s H1N1 vaccine are just now in 
progress and results may not be available for several 
weeks or months.  Nonetheless, there is every reason to 
expect that VE for this year’s H1N1 vaccine will be similar 
to what has been observed for many years for routine 
seasonal influenza vaccines.  Thus, whether viewed from 
the individual or from the broader societal perspective, 
the value of influenza vaccination remains high and needs 
to be strongly recommended to our patients and to the 
public. 
 
(Continued from page 8) 
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Table 1: Examples of Factors that can variably affect observed effectiveness of influenza virus vaccines* 
Factor affecting VE Column A 
Tendency towards higher VE 
Column B 
Tendency toward lower VE 
1) Antigenic Fit between vaccine 
virus and circulating virus 
Good fit Less good fit 
2) Outcome measured in the VE 
study 
Death, hospitalization or pneumonia 
due to laboratory-proven influenza 
Doctor’s visits, episodes of ILI 
3) Age of vaccinees Older children, young adults Very young children and older adults 
4) Health status of vaccinees Generally healthy Underlying immunologic or chronic 
disease 
5) # doses previously received** 2 doses 1 dose 
* The table summarizes relationships between factors and VE which generally but not invariably hold.  For example, in some studies 
some of these (and other) factors push VE results one way while others push them in the opposite direction.  
** This applies to children <9 years of age and explains the recommendation that “…children aged 6 months–8 years who have not 
received vaccination against influenza previously should receive 2 doses of vaccine the first year they are vaccinated.” 10 (Note this 
age group applies to seasonal influenza vaccines, two doses of the H1N1 vaccine are recommended for children through age 9.11  
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Table 2:  Schematic Perspective on the Value of Influenza Vaccination* 
Consideration Measles Vaccine Influenza Vaccine 
Vaccine effectiveness 1 dose: ~90% 
2 doses: ~95% 
~ 70% (~50-90% depending on many 
factors such as those shown in Table 1) 
US Cases per year if no vaccine ~4,000,000  (1 birth cohort) ~30,000,000 (e.g., if 10% of USA 
population would get influenza) 
Case fatality rate ~1/1000 ~1/1000 
Fatalities per year if no vaccine ~4,000 ~40,000 
Annual fatalities potentially averted with very high 
vaccine coverage: assuming only “direct” 
protection 
~ 3,800 ~28,000 
Annual fatalities potentially averted with high 
vaccine coverage: taking into account also 
“indirect” population benefits of vaccination (“herd
-immunity”) 
~4,000 ~ 32,000 
Purpose of vaccine from individual perspective Provides high level of protection 
against measles 
Provides good level of protection 
against influenza 
Purpose of vaccination from a societal perspective Key tool which (except for 
importations) has allowed for 
elimination of measles from the USA 
Mitigation of impact of influenza: e.g., 
decrease in morbidity, mortality, school 
and work days lost, and impact on the 
health-care system. 
* Numbers shown are illustrative, and especially for influenza illustrate expected orders of magnitude. For influenza, expected numbers 
of cases and deaths  would depend on infectiousness and virulence of circulating strains, vaccine coverage, vaccine effectiveness and 
other factors. 
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Box 1. Contraindications and Precautions for LAIV Administration 
LAIV is approved for use in healthy people 2-49 years of age who are not pregnant.  
The effectiveness or safety of LAIV is not known for the following groups and they should not receive LAIV:  
♦ Persons who have chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, 
neurological/neuromuscular, hematological or metabolic disorders (including diabetes), immunosuppression 
(including immunosuppression caused by medications or by HIV)  
♦ Children 2-4 years of age with wheezing in the past 12 months  
♦ Children or adolescents receiving aspirin or other salicylate therapy  
♦ Pregnant women  
♦ People who have a severe allergy to chicken eggs or who are allergic to any LAIV components  
♦ Persons < 2 years or those >50 years  
The following are precautions to receiving LAIV:  
♦ Guillain-Barré Syndrome (GBS) within 6 weeks following a previous dose of an influenza vaccine  
♦ Moderate or severe illness with or without fever 
♦ Healthcare providers and others with close contact to certain severely immunosuppressed persons A,B should either 
not receive LAIV or avoid contact with such persons for 7 days after receiving LAIV 
Are you using LAIV in Your Practice? 
Beginning December 10, 2009, DHEC expanded the 
recommended groups for H1N1 LAIV to all healthy, non-
pregnant persons 
ages 2 through 49 
years, whether or not 
they are in one of the 
H1N1 vaccine target 
groups (Box 2).  This 
will not apply to the 
inactivated injectable H1N1 vaccines.  Please order (if 
you are providing the H1N1 vaccine in your 
practice) or recommend (if you are not providing 
the H1N1 vaccine in your practice) the H1N1 LAIV 
to the appropriate patients in your practice.  If you 
are interested in becoming an H1N1 vaccine provider, 
please contact the DHEC Immunization Division at 800-
277-4687 or immunize@dhec.sc.gov. 
The H1N1 LAIV received full FDA approval on September 
15, 20093.  It is not experimental, it has been 
tested, no short cuts were made to achieve FDA 
approval, and it is not being used under an 
emergency status.  The vaccine does not contain 
adjuvants and is made in exactly the same way and using 
the same facilities as the seasonal LAIV.  H1N1 LAIV is as 
safe as the injectable vaccine and works well in children 
and adults1.  Common side effects of the H1N1 LAIV 
include runny nose, headache, sore throat, cough, and 
wheezing.  
The H1N1 LAIV contains a live virus that has been 
weakened.  It does not cause influenza in either vaccine 
recipients or the close contacts of those who have 
received the vaccine1.  In a randomized trial, the LAIV 
virus was found in the nose of only 1 out of 99 children 
who were childcare center contacts of children vaccinated 
with LAIV.  However, that one child had only URI 
symptoms and did not develop fever or influenza4.  
(Continued from page 1) 
(Continued on page 12) 
Footnotes for Box 1: 
A. Immunosuppressed patients who require care in a protective environment (typically defined as a specialized patient-care area with 
a positive airflow relative to the corridor, high-efficiency particulate air filtration, and frequent air changes), e.g., patients with 
hematopoietic stem cell transplants. 
B. Transmission of the LAIV virus from a recently vaccinated person causing influenza in a contact has not occurred. The reason for 
avoiding LAIV among healthcare providers (and other close contacts) of certain severely immunocompromised persons is the 
theoretical risk that the LAIV virus might be transmissible to severely immunosuppressed persons, and cause influenza. 
Using LAIV in your 
practice would allow more 
of your patients to be 
protected from influenza. 
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H1N1 LAIV can be used to vaccinate healthcare providers.  
The only precaution to vaccinating healthcare providers 
with LAIV is for those who care for certain severely 
immunosuppressed patients who are in protective 
environments (Box 1, footnote A).  Otherwise, H1N1 LAIV 
can be given to any other group of healthcare providers 
including those who care for pregnant women, neonatal 
intensive care unit patients, other groups of patients with 
lesser degrees of immunosuppression (e.g., persons with 
diabetes, persons with asthma who take corticosteroids, 
persons who have recently received chemotherapy or 
radiation but who are not being cared for in a protective 
environment as previously defined, or persons infected 
with HIV), and persons in all other groups at high risk for 
influenza1.  
DHEC encourages providers to take advantage of the 
available supply of H1N1 LAIV.  This vaccine is safe to 
use for many healthcare providers and their patients and 
is an effective way to prevent influenza, without the pain 
of an injection. 
(Continued from page 11) 
Are you using LAIV in Your Practice? 
Box 2: Initial Target Groups for H1N1 Vaccine Administration 
ACIP recommends that programs and providers provide vaccine to all persons in the following five initial target groups 
as soon as vaccine is available (order of target groups does not indicate priority): 
♦ pregnant women, 
♦ persons who live with or provide care for infants aged <6 months (e.g., parents, siblings, and child care providers), 
♦ health-care and emergency medical services personnel,  
♦ children and young adults aged 6 months–24 years, and 
♦ persons aged 25–64 years who have medical conditions that put them at higher risk for influenza-related 
complications. 
Recommended website:  
http://www.cdc.gov/h1n1flu/vaccination/vaccine_safety_qa.htm 
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Recommendations of the Advisory Committee on 
Immunization Practices (ACIP), 2009. Morbidity and 
Mortality Weekly Report, 58, RR-10. Retrieved from 
http://www.cdc.gov/mmwr/PDF/rr/rr5810.pdf 
The H1N1 vaccine is not 
experimental, it has been 
tested, no short cuts were made 
to achieve FDA approval, and it 
is not being used under an 
emergency status 
Image Source: www.shotnurse.com 
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What is syndromic surveillance?  
Syndromic surveillance is the systematic, ongoing 
collection, collation, analysis, and interpretation, in real-
time, of existing health data essential for the planning, 
implementation, and evaluation of public health practice 
and emergency response.  The term “syndromic” applies 
to surveillance using health-related data that precede a 
diagnosis.  Analysis of these data sources may signal 
sufficient probability of a case or an outbreak to warrant 
further public health response.   
There are several data sources that are used for 
syndromic surveillance, which many be categorized into 
clinical and non-clinical.  Clinical data sources include 
emergency department patient visits, laboratory testing 
orders, 911 calls, and ambulance dispatch.  Unlike 
traditional surveillance, syndromic surveillance does not 
use actual diagnoses.  For example, symptoms (patient 
chief complaints) are used for clinical data and presumed 
symptoms for some non-clinical data (e.g., “sick” or “not 
sick” for absentee data).   
The purpose of syndromic surveillance is to detect 
outbreaks, whether natural or man-made, earlier.  This 
earlier detection allows for a timelier public health 
response than would be possible with traditional 
surveillance.  Syndromic surveillance also provides 
situational awareness during large-scale outbreaks of 
public health significance.  Syndromic surveillance can 
also be used to monitor sentinel events that may fall 
under the radar of more traditional surveillance systems. 
South Carolina Aberration Alerting Network 
(SCAAN) 
The South Carolina Aberration Alerting Network (SCAAN) 
is a unified syndromic surveillance system for South 
Carolina that includes data streams from SC hospital 
emergency department chief-complaint and admissions 
data, Poison Control Center call data, over-the-counter 
(OTC) pharmaceutical sales surveillance, and the Center 
for Disease Control and Prevention (CDC) BioSense 
biosurveillance system.   
For this issue of Epi Notes, there will be a focus on the SC 
hospital emergency department syndromic surveillance.  
More information on the other segments within the 
SCAAN system will be available in future issues of Epi-
Notes.  
SC Hospital Emergency Department Syndromic 
Surveillance 
Data Acquisition 
Syndromic surveillance begins with the acquisition of chief 
complaint data from participating emergency 
departments.  Currently, the Medical University of South 
Carolina (MUSC), Greenville Hospital System, Self-
Regional Healthcare, Roper, St. Francis, and Kershaw 
Health are sending daily feeds of their emergency 
department patient chief complaints to DHEC.  Several 
other hospital facilities, such as Laurens County Health 
Care System, Conway Medical Center, Grand Strand 
Regional Medical Center, AnMed, Oconee Medical Center, 
and McLeod Health Systems are all close to “going live” 
with the SCAAN system.   
These daily patient chief complaints are gathered from 
existing patient information systems and are electronically 
transferred via a simple and secure file interface to a 
central state server.  This operation generally requires no 
personnel time after the process for generating and 
transferring the data file has been established.  The daily 
feeds are received the following morning by DHEC and 
contain information from the previous day.  The chief 
complaint data are then classified into pre-determined 
syndromes.  Hospital-specific syndromic reports (pdf 
format) are sent back daily to each hospital and their 
infection preventionists.   
Data Analyses & Interpretation 
Early Aberration Reporting System (EARS) methods 
were developed by the CDC to analyze real-time public 
health surveillance data without needing historical data.  
EARS uses a running baseline consisting of the average 
number of counts for a syndrome from a previous 7-day 
period and compares current syndrome counts with that 
previous average; it performs analysis via cumulative sum 
(CUSUM) methods.  For more information on EARS 
analysis, go to http://www.bt.cdc.gov/surveillance/ears/ 
Following is a graphical output from the EARS software of 
the “Respiratory” syndrome category using data from one 
of our current healthcare providers.  During this one-
month period, aberrations from the running CUSUM 
indicated days requiring further investigation.  Some 
examples of patient chief complaints that were included 
(Continued on page 14) 
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Himal Dhotre, MPH, Syndromic Surveillance Epidemiologist 
Dan Drociuk, Director, Epidemiologic Response/Enhanced Surveillance Section 
SC DHEC Division of Acute Disease Epidemiology 
Page 14 Winter 2010 Epi Notes 
in developing the “Respiratory” syndrome category are 
“difficulty breathing”, “chest cold”, “pneumonia”, 
“respiratory difficulty”, “gasping”, “pulmonary”, etc.  The 
C1C2C3 flag (diamond-shaped) indicated a sharp increase 
in the number of emergency room visits due to a 
respiratory-like illness for that hospital on that day.   
Syndromic surveillance occurs prior to diagnosis, 
therefore, a close working relationship between the data 
provider and public health for interpretation of 
aberrations is required.  Based upon both local “domain 
knowledge” (i.e., the healthcare facility) and broader 
public health awareness of broader issues (i.e., Regional 
or statewide outbreaks, increased national surveillance) 
collaboration is paramount.   
For example, if multiple aberrations (“flags”) occur on 
multiple days, Public Health would contact the infection 
preventionist of the healthcare facility providing the data.  
Together they would work to determine, via casual 
inquiries or formal investigations, if these flags indicate a 
real event or a false-positive signal.  With additional 
experience and modifications, the number of false-
positive flags will decrease.  However, the close working 
relationship between the healthcare system and public 
health will always need to be maintained.  These 
relationships are the key to surveillance, both traditional 
and syndromic. 
As with any surveillance system, one must be cognizant 
of limitations.  Questions regarding completeness of data, 
representativeness, flexibility, etc. are factors to be 
considered with any surveillance system.  Hospital-based 
chief-complaint data analysis is another “arrow in the 
quiver” of ways to monitor and respond to events of 
public health significance.  In subsequent issues, we will 
discuss other non-traditional sources of data. 
Getting Started 
SC DHEC will provide software free of charge, and will 
also provide support and assistance in implementing the 
transfer and analysis of syndromic data.  For more 
information regarding syndromic surveillance in South 
Carolina and how you can participate, please feel free to 
contact Himal Dhotre (dhotrehc@dhec.sc.gov) or Dan 
Drociuk (drociukd@dhec.sc.gov). 
Reference 
Buehler JW, Berkelman RL, Hartley DM, Peters CJ. Emerg 
Infect Dis 2003; 9 (10):1197-1204)  
(Continued from page 13) 
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Year-to-Date Summary of Reportable Conditions ‡ 
January 1, 2009 to December 11, 2009 
Reportable Condition Confirmed Probable Total 
Animal Bites – PEP recommended* 339 ** 339 
Aseptic Meningitis 78 0 78 
Brucellosis 2 0 2 
Campylobacter enteriditis 252 3 255 
Cryptosporidiosis 57 2 59 
Cyclosporiasis 1 0 1 
Dengue fever 0 1 1 
Ehrlichiosis, chaffeensis 0 3 3 
Ehrlichiosis, ewingii 1 0 1 
Giardiasis 97 0 97 
Haemophilius influenza, invasive 71 0 71 
Hemolytic uremic syndrome, post-diarrheal 2 0 2 
Hepatitis A, acute 58 0 58 
Hepatitis B, acute 50 3 53 
Hepatitis B, chronic 118 472 590 
Hepatitis C, acute 1 1 2 
Hepatitis C, chronic or past 3312 7 3319 
Influenza, human isolates (not novel H1N1) 373 0 373 
Influenza, Novel Influenza A Virus Infections (H1N1) 1913 23 1936 
Legionellosis 14 1 15 
Listeriosis 12 0 12 
Lyme disease 17 14 31 
Malaria 5 0 5 
Meningococcal disease (Neisseria meningitidis) 10 1 11 
Mumps 2 0 2 
Pertussis 210 21 231 
Psittacosis 0 1 1 
Rocky Mountain Spotted Fever 3 15 18 
Salmonellosis 1118 9 1127 
Shiga toxin-producing Escherichia coli (STEC) 20 2 22 
Shigellosis 116 2 22 
Streptococcus group A, invasive disease 72 0 72 
Streptococcus group B, age <90 days 41 0 41 
Streptococcus pneumoniae, invasive 438 0 438 
Varicella (only outbreak associated or hospitalized cases are reportable) 109 14 123 
Vibrio infections (non-cholera) 12 1 13 
Yersiniosis 8 0 8 
‡ To save space, several conditions with zero reported cases in 2009 were omitted from this list. 
*  Animal bites with PEP recommended: Bat-62; Cat-71; Dog-105; Farm Animal-19; Fox-10; Raccoon-47; Wild-10; Other-15.  
** Probable cases status is not allowed for this condition.  
West Nile Fever 1 2 3 
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FOR DISEASE REPORTING 
For immediately reportable conditions, call your local county 
health department or, for after hours, call 1-888-847-0902.  
Routine reports may be phoned in to your local health 
department or mailed on a completed DHEC DISEASE 
REPORTING CARD (DHEC 1129.)  Local county health 
department numbers are listed on the Official List of 
Reportable Conditions.   
For a copy of the current Official List of Reportable 
Conditions, call 803-898-0861 or visit www.scdhec.gov/
health/disease.index.htm.  
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